Hepatocellular Carcinoma Survival Rates Show Improvement

TOPLINE:
Survival rates for patients with hepatocellular carcinoma (HCC) have improved, but overall survival remains low. Early detection and treatment significantly enhanced survival outcomes between January 1, 2006, and December 31, 2019.
METHODOLOGY:
Researchers conducted a retrospective cohort study including 3441 adult patients diagnosed with HCC. The study aimed to evaluate survival trends among patients with HCC, the most common cause of cancer-related morbidity and mortality globally. The incidence of HCC has more than doubled in the United States over the past two decades and is expected to continue increasing.
The study was conducted within the Kaiser Permanente Northern California health system, with patients categorized into the eras of 2006-2012 and 2013-2019, and follow-up data collected on December 31, 2020.
Data collection included patient demographics, disease factors, treatment types, and survival outcomes, with statistical analysis performed from January 2021 to June 2024.
Treatment modalities were extracted from electronic health records using specific medical codes, and survival probabilities were estimated using the Kaplan-Meier method.
TAKEAWAY:
Researchers found that survival rates for patients with HCC improved significantly between 2006-2012 and 2013-2019, particularly for those receiving curative treatments.
Patients with early-stage disease (Barcelona Clinic Liver Cancer [BCLC] stage O or A) had higher survival probabilities than those with intermediate or advanced stages.
Multivariable analysis showed that factors such as age ≥ 70 years, male sex, advanced BCLC stage, and higher alpha-fetoprotein levels were associated with higher all-cause mortality.
Asian or Other Pacific Islander race and ethnicity were associated with lower all-cause mortality than non-Hispanic White patients.
IN PRACTICE:
“The trends observed…clearly demonstrate the benefits of early detection, as patients with early-stage disease who received curative treatments had the best survival; this effect became more pronounced in recent years. This study also highlights important demographic factors associated with favorable survival, which may inform treatment allocation, particularly with respect to liver transplant,” wrote the authors of the study.
SOURCE:
The study was led by Mignote Yilma, MD, of Kaiser Permanente in Oakland, California. It was published online on September 24 in JAMA Network Open.
LIMITATIONS:
The study’s retrospective nature may introduce bias. Mortality data for 2020 were only captured if documented within the electronic health records, potentially missing some deaths. The study period did not fully capture the effects of newer treatments such as transarterial radioembolization or newer systemic immunotherapies.
DISCLOSURES:
The study was supported by grants from Kaiser Permanente Community Health. No conflicts of interest disclosures were reported.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
 
Send comments and news tips to [email protected].